Clinical

Patients in this study, who had overall significantly higher scores than controls, fell into 3 categories of psychological risk from temporal lobe epilepsy (TLE) based on analysis with unsupervised machine learning.

Brian Keegan, MD, PhD, and Michael Cameron, MD, FAAD, describe treatment options for patients with atopic dermatitis.

Dr Casey Butrus drives a discussion highlighting typical patient presentations of AD.

The DRCR Retina Network is undertaking research to develop preventive strategies for diabetic eye disease, explained Jennifer K. Sun, MD, MPH, associate professor of ophthalmology and chief of the Center for Clinical Eye Research and Trials, Harvard Medical School; and chair, DRCR Retina Network.

This cross-sectional observational study found several factors associated with whether a patient had sufficient lung cancer risk factor documentation in the electronic health record.

Results from 2 late-stage trials evaluating generalized myasthenia gravis therapies indicated both drugs, rozanolixizumab and zilucoplan, have potential as targeted treatment options.

Mark A. Socinski, MD, executive director of the AdventHealth Cancer Institute, shares his insight on liquid- and tissue-based biopsies and their clinical utility in non–small cell lung cancer (NSCLC).

Investigators wanted to assess endoscopic appearance, wall thickness, histology, and dysphagia score for eosinophilic esophagitis (EoE).

Key opinion leaders discuss clinical and cost considerations for treating patients diagnosed with geographic atrophy.

A medical expert discusses preauthorization requests and requirements for cardiovascular disease treatment, commenting on an abstract presented at the ACC 2023 Annual Scientific Session and Expo and World Congress of Cardiology.

Researchers are beginning work on a double-blind randomized controlled trial to test the results of this preliminary study.

Expert panelists discuss considerations for RRMM treatment strategies.

Jeffrey Matous, MD, leads a panel discussion surrounding the use of bispecifics treatment of relapsed / refractory multiple myeloma.

The American Society for Radiation Oncology (ASTRO) and European Society for Radiotherapy and Oncology (ESTRO) jointly released a clinical guideline on the use of definitive local therapy for the treatment of oligometastatic non–small cell lung cancer (NSCLC).

Investigators found patients with acute coronary syndrome were 3 times more likely to die in the hospital.

The antibody drug conjugate received FDA approval in November 2022.

The data highlight that silent cerebral infarcts represent just a portion of brain injury that occurs in patients with sickle cell disease (SCD), and brain volume can serve as another potential biomarker of brain injury in those with the disease.

In this phase 1 trial, researchers sought to investigate whether ruxolitinib cream is safe and tolerable in children aged 2 to 17 with atopic dermatitis (AD).

People with myasthenia gravis (MG) had a higher risk of hospitalization for COVID-19 compared to the general population and a control group of people with rheumatoid arthritis (RA).

Two-year data on MRI, efficacy, and safety findings from the long-term safety extension study of the investigational Bruton tyrosine kinase (BTK) inhibitor tolebrutinib for relapsing multiple sclerosis were presented in a pair of posters at the American Academy of Neurology 2023 annual meeting.

Older people with psoriasis had a roughly 50% higher risk of being diagnosed with a malignancy, investigators found.

The projected cost reductions held both for patients switching from a different extended-half-life product and for patients switching from a standard-half-life product.

Tolebrutinib is a Bruton tyrosine kinase (BTK) inhibitor that is being investigated for use in patients who have relapsing multiple sclerosis (MS); investigators presented safety data from a long-term extension study of the phase 2b dose-finding trial.

By better understanding the nature of atopic dermatitis and its varying comorbidities, providers might be able to better predict patient outcomes, said Raj Chovatiya, MD, PhD, assistant professor of dermatology, Northwestern University Feinberg School of Medicine.

Key opinion leaders navigate diagnostic challenges associated with atopic dermatitis.

Casey Butrus, PharmD, leads a panel of experts in a discussion surrounding atopic dermatitis.

These insights represent the first characterization of risk factors for respiratory failure–related hospitalization among patients with sarcoidosis‐associated pulmonary hypertension (SAPH).

Terminology and concepts relevant to the care of transgender and gender-diverse individuals and best practices for optimizing neurologic care in this patient population were covered in the session “Neurologic Conditions in Transgender Patients” on Sunday, April 23, at the American Academy of Neurology annual meeting.

Gene therapy has the promise of being one and done, but it isn’t always that way for all patients, which leaves questions about where these therapies fit in the commercial landscape, said Charles C. Wykoff, MD, PhD, of Retina Consultants of Texas and the Blanton Eye Institute at Houston Methodist Hospital.

These findings underscore the need for improved bleed protection and hemophilia care for those with all severities of the disease.